Deutetrabenazine interactions

Food & lifestyle

• alcohol

  Moderate

  Synergy

  Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

  What to do: Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

  5 sources

  1. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
  5. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):

Conditions

Conditions in which Deutetrabenazine needs care, as documented in this source.

• Depressive Disorder

  Major

  The use of deutetrabenazine is contraindicated in patients with Huntington's disease who are suicidal, or have untreated or uncontrolled depression. Deutetrabenazine can increase the risk of depression and suicidal thoughts and behavior in these patients. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation.

  1 source

  1. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):

• Liver Diseases

  Major

  The use of deutetrabenazine is contraindicated in patients with hepatic impairment. The effect of hepatic impairment on the pharmacokinetics of deutetrabenazine and its primary metabolites has not been studied; however, in a clinical study conducted with a closely related VMAT2 inhibitor, there was a large increase in exposure to this drug and its active metabolites in patients with hepatic impairment.

  1 source

  1. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):

• Long QT Syndrome

  Major

  The use of deutetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

  1 source

  1. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):

• Neuroleptic Malignant Syndrome

  Moderate

  Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission such as, deutetrabenazine. Deutetrabenazine should be used with caution in patients presenting similar signs and symptoms of NMS. Clinicians should be alerted to the signs and symptoms associated with NMS. Recurrence of NMS has been reported with resumption of drug therapy. If treatment with deutetrabenazine is needed after recovery from NMS, patients should be monitored for signs of recurrence.

  1 source

  1. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):

• Parkinson Disease

  Moderate

  The use of vesicular monoamine transporter 2 (VMAT2) inhibitor, such as valbenazine and deutetrabenazine may cause parkinsonism in patients with tardive dyskinesia. These agents should be used with caution in patients with parkinson disease or those presenting with parkinson-like symptoms such as, falls, gait disturbances, tremor, drooling and hypokinesia. It is recommended to reduce the dose or to discontinue treatment in patients who develop clinically significant parkinson-like signs or symptoms while on treatment with these agents.

  2 sources

  1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):
  2. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):